Lupin Receives USFDA approval for ranluspec biosimilar referencing Lucentis
Pharmaceutical firm Lupin Ltd on Thursday (June 4) said it has received approval from the United States Food and Drug Administration (USFDA) for Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar referencing Lucentis of Genentech. The company said Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vial and pre-filled syringe (PFS) presentations….
